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Abstract
Hypertension is a disorder prevalent in adults around the world and is a
common attributable cause of heart disease and mortality [1]. Calcification is
much more common in the aortic valve than the other three heart valves [2].
Aortic valve interstitial cells (VICs), the principal cell type found in the human
aortic valve, have been linked to disease development when they change in
phenotype to become osteoblast like cells [3]. The phenotypes of these cells play
a role in the development of calcification in the aortic valves [4].
Angiotensin II is a hormone in the body that has been implicated to
stimulate inflammation in heart valves and is linked to the development of heart
valve disease [5][6]. Losartan (AT1R antagonist) and PD123319 (AT2R
antagonist) are commercially available drugs to prevent ang-II from binding to
ang-II receptors on the cells [7][8]. There are certain protein signatures (RUNX2,
αSMA, Ki-67, TGFβ1, Vimentin, and Calponin) that can be observed to
determine if VICs are being activated in the presence of ang-I or ang-II with and
without the presence of receptor antagonists.
Cells were cultured in 10% media with six treatment groups and one
control: angiotensin I (ang-I) without an inhibitor, angiotensin II (ang-II) without an
inhibitor, angiotensin I + Losartan (ang-I + Los), angiotensin II + Losartan (ang -I
+ Los), angiotensin I + PD123319 (ang-I + PD), and angiotensin II + PD123319
(ang-II + PD). Expression of protein signatures was assessed using
immunocytochemistry. Results displayed phenotypic change in the form of
increased expression of protein signatures in VICs with treatment groups. Most
VICs were inhibited in the presence of losartan, demonstrating that the binding of
ang II to AT1R is causing increased activation of the VICs.
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Introduction:
The heart is a vital organ that is needed for survival [9]. It consists of four
chambers: the right and left atria and the right and left ventricle, and four valves:
the tricuspid, pulmonary, mitral, and aortic. The aortic valve is what enables
freshly oxygenated blood to flow from the left ventricle to the aorta and on to the
body’s systemic circulation [9].

Figure 1: Image illustrating flood flow through heart [10]

Aortic valve calcification occurs when calcium deposits form on the aortic valve,
causing a narrowing in the opening of the valve that reduces blood flow. When
flow is restricted, it results in aortic valve stenosis. This is a common early sign of
heart disease [11]. It causes the heart to work harder to pump blood to the body
[10].

Figure 2: Healthy and aortic and aortic valve stenosis visualization [12]
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Calcification of the aortic valve is much more common than calcification of the
other three heart valves. Calcific aortic stenosis is the 3rd most prevalent
cardiovascular disease in the United States [2]. Valvular aortic stenosis caused
by calcification of cells is commonly associated with hypertension, a disease that
affects 2% of the population above the age of 65 [13].
Aortic valve interstitial cells (VICs), the principal cell type found in the human
aortic valve, have been linked to disease development when they change in
phenotype to become osteoblast-like cells [3]. The phenotypes of these cells play
a role in the development of calcification in the aortic valves [4]. The calcification
of aortic valves is not due to random degeneration, but rather an active process
of bone formation in the aortic valve associated with certain cell phenotypes [14].
VIC phenotypes include quiescent (qVICs), activated (aVICs), and osteoblastic
(obVICs). Quiescent VICs are responsible for maintaining normal valve functions,
and are normally inactive. If the cells are injured or stressed, they have a
tendency to become aVICs, which can easily differentiate into diseased obVICs
[15]. Active VICs are a very important part of the wound repair process, and are
usually eliminated by apoptosis once they have served their purpose. If this
apoptosis fails it may result in pathological fibrosis, chronic inflammation, and
calcification, which leads to clinical valve diseases [5].
qVICs
quiescent

aVICs
activated

obVICs
diseased

Figure 3: Illustration of how Valve Interstitial Cells can go from quiescent, to activated,
and then osteoblastic/diseased

Angiotensin II (ang-II) is a hormone in the body partially responsible for
regulating blood pressure, cardiac function, and plasma volume. It’s of incredible
importance in hypertension and is a fundamental effector of the renin-angiotensin
system [6][16]. Studies have shown that ang-II has been implicated to stimulate
inflammation in heart valves and is linked to the development of heart valve
disease [5][6]. Angiotensin receptor blockers are among some of the only
standard evidence-based heart failure therapies [13]. All national guidelines
recommend an angiotensin receptor blocker as a part of anti-hypertension
therapy [1]. Recently, there has been clinical evidence that long-term blocking of
ang-II conversion could have a protective effect against carcinogenesis [6].
Renin is an enzyme produced by the kidneys and acts on the protein
angiotensinogen that’s formed by the liver to produce the hormone Angiotensin I
(ang-I). Ang-I can be transformed into ang-II in the blood via the angiotensinconverting enzyme (ACE). This is commonly referred to as the renin-angiotensin
System, or RAS [17]. Ang-II (ang-I) can then bind to two different ang-II receptors
on cells that mediate the majority of its effects, angiotensin II type 1 receptor
(AT1R) and angiotensin II type 2 receptor (AT2R) [6].
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There are currently four classes of medications that focus on various aspects of
the renin-angiotensin system pathway in an effort to combat hypertension. These
include angiotensin converting enzyme (ACE) inhibitors, aldosterone antagonists,
direct renin inhibitors, and ang-II receptor blockers (ARBs) [1]. The two ARBs
that will be utilized in this experiment are Losartan and PD123319. In general,
ARBs are better tolerated and produce fewer side effects than ACE inhibitors
[18]. Unfortunately, ACE inhibitors are only partially successful in inhibiting the
formation of ang-II, and are related to several adverse effects such as chronic
cough and angioedema [1][18].
Losartan (AT1R antagonist) and PD123319 (AT2R antagonist) are commercially
available drugs to prevent ang-II from binding to ang-II receptors on the cells
[7][8]. AT2R expression is increased in tissues experiencing hypertension,
cardiac hypertrophy, and ischemic heart disease. AT2R negatively regulates
AT1R signaling, but the precise mechanism that makes this happen is poorly
understood [19]. AT1R activates growth-promoting pathways and mediates ang-II
effects such as vasoconstriction and increased blood pressure as well as
detrimental effects such as inflammation. AT2R has been linked to producing
opposite effects, such as vasodilation, hypotension, and possible inhibition of
AT1R [16].

Figure 4: Illustration of ang-I to ang-II pathway with AT1R and AT2R inhibiting medications

There are certain protein signatures that can be observed to determine if VICs
are being activated in the presence of ang-I or ang-II with and without the
presence of receptor antagonists. If the marker Vimentin were up regulated, it
would indicate more quiescent VICs [24]. If the markers αSMA, Ki-67, TGFβ1,
and Calponin are up regulated, it’s an indicator of increased aVICs.
[5][21][20][15][22][23]. These aVICs can easily differentiate into obVICs, which
regulate osteogenesis and the calcification process [15]. ObVICs secrete
RUNX2, so if this marker is present in the sample cells are likely to be calcified
[14][15]. It is important to look for these markers in to test whether the VICs are
changing in phenotype when exposed to ang-I and ang-II.
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Table 1: Table simplifying protein signature markers, their roles in the body, and what an upregulation in results would indicate. Sources: [5][21][20][15] [22][23][24][14]

Marker

Role in the Body

Up-regulation would
mean

RUNX2

Transcription factor necessary for
bone formation
Smooth muscle actin, Marker for
aVIC activation

More osteogenic VICs

Ki-67

Protein with important function in
cell division

More activated VICs

TGFβ1

Growth factor secreted by aVICs,
also increases overexpression of
αSMA
Proteins expressed in inactive
VICs
Protein shown to regulate
smooth muscle cell differentiation

More activated VICs

αSMA

Vimentin
Calponin

More activated VICs

More quiescent VICs
More activated VICs

Objectives and Hypothesis
The objective of this research was to better understand how the reninangiotensin system affected the phenotype of valve interstitial cells both with and
without the presence of inhibitors.
There are two main questions we were hoping to answer:
1. Are VICs changing in phenotype in the presence of ang-I and ang-II?
2. Is RAS affecting the phenotype of VICs due to the binding of ang-II to AT1R or
AT2R?
We hypothesized that the renin-angiotensin system will alter the phenotype of
VICs. Additionally, we hypothesized that VICs will become more osteogenic in
the presence of ang-II and will experience up-regulation in markers for aVICs and
obVICs in its presence.
Methods:
Preparing Media
To prepare 2% media for coverslips
In order to make 500mL of media total, 2% needs to be FBS, 1% needs to be
Penicillin Streptomycin, 1% needs to be HEPES, and the rest should consist of
DMEM media. In order to accomplish this, 10mL of 2% FBS, 5mL of Penicillin
Streptomycin, and 5mL of HEPES was added to 480mL of DMEM media.
To prepare 10% media for culture in the flask
In order to make 500mL of media total, 10% needs to be 2%FBS, 1% needs to
be Penicillin Streptomycin, 1% needs to be HEPES, and the rest should consist
7

of DMEM media. In order to accomplish this, 50mL of 2% FBS, 5mL of Penicillin
Streptomycin, and 5mL of HEPES was added to 440mL of DMEM media.
The entire 500mL media mixture was run through a filter, using an aspirator as a
vacuum.
Sterilizing cover slips
18mm diameter cover slips were autoclaved for one hour.
Cell Culture and Seeding
A T175 flask confluent with porcine valvular interstitial cells from an aortic valve
growing in 10% media was prepared in advance. All cell culture was performed in
a biosafety cabinet, and all outside materials were sterilized with 70% ethanol
before entering the sterile environment. 100µL of gelatin was placed onto each
autoclaved coverslip and incubated at 37 degrees Celsius and 5% CO2 for one
hour. Seven 12 well plates were set out, and 1mL of PBS was pipetted into each
well. A coverslip was placed in each well, with the gelatin side face up. The PBS
was aspirated from the wells are replaced three times to wash the coverslips.
2mL of .25% trypsin was pipetted into the confluent T175 flask and left to
incubate for 2 minutes. The T175 flask was removed from the incubator and
tapped firmly against the inside of a wrist to loosen the cells from the bottom of
the flask. Cells were observed under a microscope while still in the T175 flask to
ensure that they were visibly unstuck/ appeared more round than their adhered
fibroblast-like state. 15mL of 10% red media was pipetted into the T175 flask and
swirled around to cover the surface area of the flask several times to deactivate
the trypsin. All media was then pipetted out of the T175 flask and into a 50mL
centrifuge tube. The 50mL tube was centrifuged at 4 degrees Celsius for 6
minutes. The supernatant was removed and discarded by bleaching and placing
it in biohazard waste. 3mL of 2% media was pipetted into the 50mL tube
containing the pellet and mixed thoroughly until the pellet was dissolved.
Cell counting took place with a hemocytometer. 20µL of well-mixed sample was
transferred into a small eppendorf tube to take to the microscope. 10µL of
sample was pipetted into each side of the hemocytometer, and cells were
counted in the center and averaged to estimate the density of the sample. 161
cells were counted on one side and 80 cells were counted on the second side.
This averaged out to be about 119.5 ∗ 10! cells per mL of solution. Accounting for
the 3mL of media that the pellet was suspended in, centrifuge tube was
estimated to have about 3.59 ∗ 10! cells in the suspension. Each of the 84
coverslips needed to be seeded with 2,000 cells, so it was calculated that
168,000 cells were needed from the mixture.

8

84 𝑐𝑜𝑣𝑒𝑟 𝑠𝑙𝑖𝑝𝑠 ∗ 2,000 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑠𝑙𝑖𝑝 = 168,000 𝑐𝑒𝑙𝑙𝑠 𝑛𝑒𝑒𝑑𝑒𝑑
!"## #

!"## #

This number was rounded to 200,000. The equation !"#$%&! ! = !"#$%&! ! was used
to calculate the second volume number to extract the amount of cells desired. It
was calculated that 167µL of the mixture was needed from the 50mL centrifuge
tube to obtain the approximate amount of cells for the current procedure. It was
then calculated that 8.233mL of media from the 167µL would be needed for
seeding cells onto coverslips.
𝑣𝑜𝑙𝑢𝑚𝑒 2 =

!.!∗!"! ∗ !!!
!.!" ∗ !"!

= 167µL

84 𝑐𝑜𝑣𝑒𝑟 𝑠𝑙𝑖𝑝𝑠 ∗ 100µL of cell solution = 8.4mL
8.4𝑚𝐿 − 0.167𝑚𝐿 = 8.233𝑚𝐿 𝑜𝑓 𝑚𝑒𝑑𝑖𝑎 𝑓𝑟𝑜𝑚 167µL cell solution
100µL of cell solution was pipetted onto the prepared gelatin coverslips, being
careful not to break the surface tension of the media so that all cells would
remain in the center of the coverslips were places into an incubator for 2 days.
Treatment Groups
Each of the seven 12 well plates were labeled with the date (4/3/18), the name of
the cell line (VIC5), the passage number (P5), who was the primary handler for
each plate, and the treatment group. There was one treatment group for each 12
well plate: control, angiotensin I (ang-I) without an inhibitor, angiotensin II (ang-II)
without an inhibitor, angiotensin I + Losartan (ang-I + Los), angiotensin II +
Losartan (ang-II + Los), angiotensin I + PD123319 (ang-I + PD), and angiotensin
II + PD123319 (ang-II + PD).
Coverslips were treated with respective inhibitors (Losartan or PD123319) for 24
hours while the control and other non-inhibitor groups incubated in 2% media.
Afterwards, coverslips were treated with ang-I (10!! ) or ang-II (10!! ) for 2 days.
The cells had a total of 5 days on the coverslips before fixing.
12.375mL of 2% media and 125µL of Losartan (10!! ) was added into the 15mL
“Los” tube. 12.375mL of 2% media and 125µL of PD123319 (10!! ) was added
into the 15mL “PD” tube. Each 15mL tube was vortexed and placed in a water
bath. 500µL of fluid from the “Los” tube was applied to each treatment group well
that was labeled with Losartan, 24 wells in total. 500µL of fluid from the “PD” tube
was applied to each treatment group well that was labeled with PD123319, 24
wells in total. Cover slips were ensured to be completely submerged in their
respective solutions before returning them to the incubator overnight. This was
conducted for an n=2.
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ICC Immunostaining
Fixing the slides
All materials were brought to room temperature before the process began. Cells
were transported from the incubator to the fume hood and were rinsed gently 3x
in PBS. After the third wash, the PBS was aspirated from the plate wells. Each
coverslip was stained using 400µL of a 4% Paraformaldehyde (PFA), Triton-X
100, and PBS stock solution mixture in a dark fumigated environment for 10
minutes. All waste solution was aspirated and disposed of in container labeled as
“toxic”. Immediately, 3-4mL of PBS was added to each coverslip well, swirled
gently to rinse, and left to sit for 10 minutes. This process of rinsing with PBS
was repeated two more times. After the final wash, the coverslips were left to sit
in PBS at 4 degrees Celsius for the night.
Blocking
PBS was aspirated from the coverslip wells and 130µL per well of 10% goat
serum (the species of the secondary antibody) was pipetted onto the coverslips
and left to incubate at 37 degrees Celsius for 60 minutes.
Primary Stain
This was done in a light-protected environment. Primary antibody solution was
prepared in advance, and consisted of 1% goat serum (Abcam), the designated
concentration of the marker for the respective treatment group, and PBS.
Measurements were based on providing 130µL of primary antibody solution per
coverslip.
Table 2: Summary of treatment group markers, their concentration, and their species

Treatment Group
Markers
RUNX2
αSMA
Ki-67
TGFβ1
Vimentin
Calponin

Concentration Species
(1/200)
(1/100)
(1/200)
(1/100)
(1/200)
(1/200)

Rabbit
Mouse
Rabbit
Rabbit
Mouse
Rabbit

Seven 130µL drops (one for each coverslip treatment group) were placed into
eight different clean Petri dishes (one for each treatment group and a negative
control) evenly spaced out. Using forceps, coverslips were placed over the
solution cell-side down and left to incubate at 4 degrees Celsius overnight. After
the incubation period, coverslips were placed into 12-well plates cell-side up and
left to sit in PBS for 10 minutes, then washed gently with PBS two more times.
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After the final wash, the coverslips were left to sit in PBS at 4 degrees Celsius for
the night.
Secondary Stain
For each coverslip, 130µL of secondary stain was prepared. The secondary stain
consisted of 1:200 DAPI stock, 1% Goat serum, 1:200 of the appropriate
secondary antibody (goat or rabbit, Abcam) Alexa Fluor 594 conjugate, and PBS.
If a mouse primary antibody was used, a goat-anti-mouse IgG was used for the
secondary antibody. If a rabbit primary antibody was used, a goat-anti-rabbit IgG
was used for the secondary antibody. All components of the secondary stain
were mixed well with a vortex and protected from light. In addition to previously
treated coverslips, seven untreated coverslips from each treatment group were
also stained with secondary antibody to serve as a negative control.
Coverslips were incubated in the secondary stain for 1 hour and 45 minutes in
the dark. After the incubation period, coverslips were rinsed gently in PBS for
10minutes, then the PBS was aspirated and the slips were washed 3 more times
in PBS, leaving the last round of PBS sitting on the coverslips until mounting
could take place.
Mounting
One glass slide was prepared for every coverslip, fitting two coverslips per slide.
Slides were labeled with n1 or n2, the primary antibody, the date of fixing, the
name of the primary handler, and the treatment group. A drop of prolong gold
anti-fade reagent (Invitrogen #P36930) without any bubbles was placed onto the
clean slides, then the coverslips were carefully placed cell-side down into it. All
slides were laid flat in a dark environment to dry overnight, then placed in a slide
box and stored in a negative 20 degrees Celsius freezer.
Imaging
Cells were imaged with a standard epifluorescence microscope at 20x for both
DAPI and red 594. Four to five images were taken of each coverslip for both
DAPI and red 594, for a total of 8-10 pictures per coverslip. Select images were
compiled together for visual quantitative analysis. ImageJ was used to compile
DAPI and red 594 stained images.
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Results and Discussion:
RUNX2: Increased expression in ang-I and ang-II treatment groups in
comparison to the control indicating cells became more osteogenic. In the
presence of PD123319 there was less expression than in the presence of
losartan indicating AT2R receptors were blocked more.

Figure 5. Immunocytochemistry images of RUNX2 expression of the 7 treatment groups (scale bar=200µm)

αSMA: Increased in expression for ang-I & ang-II with no inhibitors, indicating
cells became more activated. In the presence of PD123319 there was more
expression than in the presence of Losartan, indicating blocking the AT1R
receptor had more of an effect suppressing this marker.

Figure 6. Immunocytochemistry images of αSMA expression of the 7 treatment groups (scale bar=200µm)
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Ki-67: Increased in expression for ang-I & ang-II, indicating cells became more
activated. In the presence of PD123319 there was more expression than in the
presence of losartan, indicating blocking the AT1R receptor had more of an effect
suppressing this marker.

Figure 7. Immunocytochemistry images of Ki-67 expression of the 7 treatment groups (scale
bar=200µm)

TGFβ1: Increased in expression for ang-I & ang-II, indicating cells became more
activated. In the presence of PD123319 & losartan there was also increased
expression, indicating blocking AT1R & AT2R receptors had no effect on this
marker for this particular incubation time.

Figure 8. Immunocytochemistry images of TGFβ1 expression of the 7 treatment groups (scale
bar=200µm)
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Vimentin: Increased in expression for ang-I & ang-II, indicating cells were more
quiescent VICs, which was an unexpected result. Interestingly enough, this
expression was equally vibrant for both ang-I and ang-II samples, indicating a
potential conversion of ang-I samples to ang-II.

Figure 9. Immunocytochemistry images of Vimentin expression of the 7 treatment groups (scale
bar=200µm)

Calponin: Increased in expression for ang-I and especially for ang-II, indicating
cells became more activated. In the presence of PD123319 and losartan there
was little expression in comparison, indicating AT1R & AT2R receptors were
blocked.

Figure 10. Immunocytochemistry images of Calponin expression of the 7 treatment groups (scale
bar=200µm)
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Negative control: No expression/ non-specific binding of the secondary reagent,
indicating no contamination of samples.

Figure 11. Immunocytochemistry images of Negative Control expression of the 7 treatment
groups (scale bar=200µm)

Conclusions, Limitations, and Future Directions:
Results displayed phenotypic changes in the form of increased expression of
protein signatures in VICs with ang-I and ang-II treatment groups when
compared with their respective controls. Most VICs were inhibited in the
presence of losartan, demonstrating that the binding of ang-II to AT1R is causing
increased activation of the VICs. If ang-II is still having the same effect it does in
the presence of PD123319 as it does in the presence of Losartan, then AT2R
must not be the receptor responsible for the phenotypic changes. It’s likely that
AT2R binding isn’t making as big of an impact on the phenotype of VICs in
comparison to binding to AT1R. To further verify this, future work should perform
more quantitative analysis over multiple time periods.
Limitations of the procedure were not enough cells used while seeding to be able
to do quantitative analysis. Cells were seeded sparsely intentionally to avoid
activating them with a high density, but the density of cells should be increased
when repeating this procedure. In the future, quantitative analysis will be done in
more confluent samples, and western blots will be conducted to further confirm
VIC phenotypic changes.
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